why choose us

First received: February 01, 2023

Clinical Trial: STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Breast Cancer

Study Type: INTERVENTIONAL


Official Title: The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer

Brief Summary: This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment.Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.

Read more